Pharmacokinetic, pharmacodynamic and biodistribution following oral administration of nanocarriers containing peptide and protein drugs

Advanced Drug Delivery Reviews

Volumn 106, Issue , 2016, Pages 367-380

  Griffin, Brendan T ^a   Guo, Jianfeng ^a   Presas, Elena ^a   Donovan, Maria D ^a   Alonso, María J ^b   O'Driscoll, Caitriona M ^a  

^a UNIVERSITY COLLEGE CORK   (Ireland)

^b Universidade de Santiago de Compostela and Instituto de Investigación Sanitaria de Santiago de Compostela   (Spain)

Author keywords

Bioavailability; Nanoparticles for oral administration; Pharmacokinetics and pharmacodynamics of peptide and protein drugs; Physiologically based pharmacokinetic modelling; Regulatory challenges

Indexed keywords

BIOCHEMISTRY; NANOPARTICLES; PEPTIDES; PHARMACODYNAMICS; PHYSIOLOGY; PROTEINS;

ABSORPTION ENHANCEMENT; BIOAVAILABILITY; ORAL ADMINISTRATION; PHYSICOCHEMICAL PROPERTY; POSSIBLE MECHANISMS; PROTEIN DRUGS; REGULATORY CHALLENGES; REGULATORY FRAMEWORKS;

PHARMACOKINETICS;

ARGINYLGLYCYLASPARTIC ACID; BOVINE SERUM ALBUMIN; CALCITONIN; CHITOSAN; CHITOSAN NANOPARTICLE; CYCLOSPORIN; DOCETAXEL; EDELFOSINE; EPIDERMAL GROWTH FACTOR; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; GOLD NANOPARTICLE; GRANULOCYTE COLONY STIMULATING FACTOR; INSULIN; INSULIN ASPART; LEUPRORELIN; LIPOSOME; MACROGOL; NANOCARRIER; NANOPARTICLE; PEPTIDE; POLOXAMER; POLY(METHYL METHACRYLATE); POLYGLACTIN; SALCATONIN; SILICA NANOPARTICLE; SOLID LIPID NANOPARTICLE; TAMOXIFEN; UNINDEXED DRUG; VACCINE; DRUG; DRUG CARRIER; PROTEIN;

ADHESION; ANTIDIABETIC ACTIVITY; AREA UNDER THE CURVE; COMPUTER MODEL; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG EXCRETION; DRUG FORMULATION; DRUG HALF LIFE; DRUG METABOLISM; HUMAN; LIPOPHILICITY; LYMPH NODE METASTASIS; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; METASTASIS INHIBITION; NONHUMAN; PARTICLE SIZE; PHARMACODYNAMICS; PHYSICAL CHEMISTRY; PREDICTION; PRIORITY JOURNAL; REVIEW; SELF EMULSIFYING DRUG DELIVERY SYSTEM; SELF MICROEMULSIFYING DRUG DELIVERY SYSTEM; SELF NANOEMULSIFYING DRUG DELIVERY SYSTEM; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; SURFACE CHARGE; SUSPENSION; TIME TO MAXIMUM PLASMA CONCENTRATION; ANIMAL; METABOLISM; ORAL DRUG ADMINISTRATION; TISSUE DISTRIBUTION;

ADMINISTRATION, ORAL; ANIMALS; DRUG CARRIERS; HUMANS; NANOPARTICLES; PEPTIDES; PHARMACEUTICAL PREPARATIONS; PROTEINS; TISSUE DISTRIBUTION;

EID: 84978543508     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2016.06.006     Document Type: Review

References (112)

1. [1] Gordon Still, J., Development of oral insulin: progress and current status. Diabetes Metab. Res. Rev. 18:Suppl. 1 (2002), S29–S37.
2. [2] Lautenschlager, C., Schmidt, C., Lehr, C.M., Fischer, D., Stallmach, A., PEG-functionalized microparticles selectively target inflamed mucosa in inflammatory bowel disease. Eur. J. Pharm. Biopharm. 85 (2013), 578–586.
3. [3] Xu, Q., Ensign, L.M., Boylan, N.J., Schon, A., Gong, X., Yang, J.C., Lamb, N.W., Cai, S., Yu, T., Freire, E., Hanes, J., Impact of surface polyethylene glycol (PEG) density on biodegradable nanoparticle transport in mucus ex vivo and distribution in vivo. ACS Nano 9 (2015), 9217–9227.
4. [4] Bourganis, V., Karamanidou, T., Samaridou, E., Karidi, K., Kammona, O., Kiparissides, C., On the synthesis of mucus permeating nanocarriers. Eur. J. Pharm. Biopharm. 97, Part A (2015), 239–249.
5. [5] X.Q, Suk, J.S., Kim, N., Hanes, J., Ensign, L.M., PEGylation as a strategy for improving nanoparticle-based drug and gene delivery. Adv. Drug Deliv. Rev. 99, Part A (2015), 28–51.
6. [6] Jani, P., Halbert, G.W., Langridge, J., Florence, A.T., Nanoparticle uptake by the rat gastrointestinal mucosa: quantitation and particle size dependency. J. Pharm. Pharmacol. 42 (1990), 821–826.
7. [7] O'Driscoll, C.M., Lipid-based formulations for intestinal lymphatic delivery. Eur. J. Pharm. Sci. 15 (2002), 405–415.
8. [8] Florence, A.T., Nanoparticle uptake by the oral route: fulfilling its potential?. Drug Discov. Today Technol. 2 (2005), 75–81.
9. [9] des Rieux, A., Fievez, V., Garinot, M., Schneider, Y.J., Preat, V., Nanoparticles as potential oral delivery systems of proteins and vaccines: a mechanistic approach. J. Control. Release 116 (2006), 1–27.
10. [10] des Rieux, A., Ragnarsson, E.G., Gullberg, E., Preat, V., Schneider, Y.J., Artursson, P., Transport of nanoparticles across an in vitro model of the human intestinal follicle associated epithelium. Eur. J. Pharm. Sci. 25 (2005), 455–465.
11. [11] des Rieux, A., Fievez, V., Theate, I., Mast, J., Preat, V., Schneider, Y.J., An improved in vitro model of human intestinal follicle-associated epithelium to study nanoparticle transport by M cells. Eur. J. Pharm. Sci. 30 (2007), 380–391.
12. [12] He, B., Lin, P., Jia, Z., Du, W., Qu, W., Yuan, L., Dai, W., Zhang, H., Wang, X., Wang, J., Zhang, X., Zhang, Q., The transport mechanisms of polymer nanoparticles in Caco-2 epithelial cells. Biomaterials 34 (2013), 6082–6098.
13. [13] Cartiera, M.S., Johnson, K.M., Rajendran, V., Caplan, M.J., Saltzman, W.M., The uptake and intracellular fate of PLGA nanoparticles in epithelial cells. Biomaterials 30 (2009), 2790–2798.
14. [14] Gaumet, M., Gurny, R., Delie, F., Localization and quantification of biodegradable particles in an intestinal cell model: the influence of particle size. Eur. J. Pharm. Sci. 36 (2009), 465–473.
15. [15] Verma, M.S., Liu, S.Y., Chen, Y.Y., Meerasa, A., Gu, F.X., Size-tunable nanoparticles composed of dextran-b-poly(D,L-lactide) for drug delivery applications. Nano Res. 5 (2012), 49–61.
16. [16] Madara, J.L., Regulation of the movement of solutes across tight junctions. Annu. Rev. Physiol. 60 (1998), 143–159.
17. [17] He, C., Yin, L., Tang, C., Yin, C., Size-dependent absorption mechanism of polymeric nanoparticles for oral delivery of protein drugs. Biomaterials 33 (2012), 8569–8578.
18. [18] Guo, J.F., Bourre, L., Soden, D.M., O'Sullivan, G.C., O'Driscoll, C., Can non-viral technologies knockdown the barriers to siRNA delivery and achieve the next generation of cancer therapeutics?. Biotechnol. Adv. 29 (2011), 402–417.
19. [19] Guo, J., Evans, J.C., O'Driscoll, C.M., Delivering RNAi therapeutics with non-viral technology: a promising strategy for prostate cancer?. Trends Mol. Med. 19 (2013), 250–261.
20. [20] Longmire, M., Choyke, P.L., Kobayashi, H., Clearance properties of nano-sized particles and molecules as imaging agents: considerations and caveats. Nanomedicine-Uk 3 (2008), 703–717.
21. [21] Bourganis, V., Karamanidou, T., Samaridou, E., Karidi, K., Kammona, O., Kiparissides, C., On the synthesis of mucus permeating nanocarriers. Eur. J. Pharm. Biopharm. 97 (2015), 239–249.
22. [22] Guo, J., Fisher, K.A., Darcy, R., Cryan, J.F., O'Driscoll, C., Therapeutic targeting in the silent era: advances in non-viral siRNA delivery. Mol. BioSyst. 6 (2010), 1143–1161.
23. [23] Prego, C., Torres, D., Fernandez-Megia, E., Novoa-Carballal, R., Quinoa, E., Alonso, M.J., Chitosan-PEG nanocapsules as new carriers for oral peptide delivery — effect of chitosan pegylation degree. J. Control. Release 111 (2006), 299–308.
24. [24] Jevsevar, S., Kunstelj, M., Porekar, V.G., PEGylation of therapeutic proteins. Biotechnol. J. 5 (2010), 113–128.
25. [25] Pawar, V.K., Meher, J.G., Singh, Y., Chaurasia, M., Surendar Reddy, B., Chourasia, M.K., Targeting of gastrointestinal tract for amended delivery of protein/peptide therapeutics: strategies and industrial perspectives. J. Control. Release 196 (2014), 168–183.
26. [26] Veronese, F.M., Pasut, G., PEGylation, successful approach to drug delivery. Drug Discov. Today 10 (2005), 1451–1458.
27. [27] Prego, C., Garcia, M., Torres, D., Alonso, M.J., Transmucosal macromolecular drug delivery. J. Control. Release 101 (2005), 151–162.
28. [28] Prego, C., Fabre, M., Torres, D., Alonso, M.J., Efficacy and mechanism of action of chitosan nanocapsules for oral peptide delivery. Pharm. Res. Dordr. 23 (2006), 549–556.
29. [29] Ponchel, G., Irache, J., Specific and non-specific bioadhesive particulate systems for oral delivery to the gastrointestinal tract. Adv. Drug Deliv. Rev. 34 (1998), 191–219.
30. [30] Huang, Y., Leobandung, W., Foss, A., Peppas, N.A., Molecular aspects of muco- and bioadhesion: tethered structures and site-specific surfaces. J. Control. Release 65 (2000), 63–71.
31. [31] Reineke, J., Cho, D.Y., Dingle, Y.L., Cheifetz, P., Laulicht, B., Lavin, D., Furtado, S., Mathiowitz, E., Can bioadhesive nanoparticles allow for more effective particle uptake from the small intestine?. J. Control. Release 170 (2013), 477–484.
32. [32] Guo, J.F., Cheng, W.P., Gu, J.X., Ding, C.X., Qu, X.Z., Yang, Z.Z., O'Driscoll, C., Systemic delivery of therapeutic small interfering RNA using a pH-triggered amphiphilic poly-L-lysine nanocarrier to suppress prostate cancer growth in mice. Eur. J. Pharm. Sci. 45 (2012), 521–532.
33. [33] Ye, L., Zeng, R., Bai, Y., Roopenian, D.C., Zhu, X., Efficient mucosal vaccination mediated by the neonatal Fc receptor. Nat. Biotechnol. 29 (2011), 158–163.
34. [34] Zhang, P., Xu, Y., Zhu, X., Huang, Y., Goblet cell targeting nanoparticle containing drug-loaded micelle cores for oral delivery of insulin. Int. J. Pharm. 496 (2015), 993–1005.
35. [35] Jin, Y., Song, Y., Zhu, X., Zhou, D., Chen, C., Zhang, Z., Huang, Y., Goblet cell-targeting nanoparticles for oral insulin delivery and the influence of mucus on insulin transport. Biomaterials 33 (2012), 1573–1582.
36. [36] Fan, T., Chen, C., Guo, H., Xu, J., Zhang, J., Zhu, X., Yang, Y., Zhou, Z., Li, L., Huang, Y., Design and evaluation of solid lipid nanoparticles modified with peptide ligand for oral delivery of protein drugs. Eur. J. Pharm. Biopharm. 88 (2014), 518–528.
37. [37] Malik, B., Goyal, A.K., Zakir, F., Vyas, S.P., Surface engineered nanoparticles for oral immunization. J. Biomed. Nanotechnol. 7 (2011), 132–134.
38. [38] Pridgen, E.M., Alexis, F., Kuo, T.T., Levy-Nissenbaum, E., Karnik, R., Blumberg, R.S., Langer, R., Farokhzad, O.C., Transepithelial transport of Fc-targeted nanoparticles by the neonatal fc receptor for oral delivery. Sci. Transl. Med., 5, 2013, 213ra167.
39. [39] Chalasani, K.B., Russell-Jones, G.J., Yandrapu, S.K., Diwan, P.V., Jain, S.K., A novel vitamin B12–nanosphere conjugate carrier system for peroral delivery of insulin. J. Control. Release 117 (2007), 421–429.
40. [40] Makhlof, A., Fujimoto, S., Tozuka, Y., Takeuchi, H., In vitro and in vivo evaluation of WGA-carbopol modified liposomes as carriers for oral peptide delivery. Eur. J. Pharm. Biopharm. 77 (2011), 216–224.
41. [41] Zhang, N., Ping, Q.N., Huang, G.H., Xu, W.F., Cheng, Y.N., Han, X.Z., Lectin-modified solid lipid nanoparticles as carriers for oral administration of insulin. Int. J. Pharm. 327 (2006), 153–159.
42. [42] Zhang, N., Ping, Q.N., Huang, G.H., Xu, W.F., Investigation of lectin-modified insulin liposomes as carriers for oral administration. Int. J. Pharm. 294 (2005), 247–259.
43. [43] Mishra, N., Khatri, K., Gupta, M., Vyas, S.P., Development and characterization of LTA-appended chitosan nanoparticles for mucosal immunization against hepatitis B. Artif. Cells Nanomed. Biotechnol. 42 (2014), 245–255.
44. [44] Mishra, N., Tiwari, S., Vaidya, B., Agrawal, G.P., Vyas, S.P., Lectin anchored PLGA nanoparticles for oral mucosal immunization against hepatitis B. J. Drug Target. 19 (2011), 67–78.
45. [45] Zhao, Y.M., Gao, L.P., Zhang, H.L., Guo, J.X., Guo, P.P., Grape seed proanthocyanidin extract prevents DDP-induced testicular toxicity in rats. Food Funct. 5 (2014), 605–611.
46. [46] Jain, S., Rathi, V.V., Jain, A.K., Das, M., Godugu, C., Folate-decorated PLGA nanoparticles as a rationally designed vehicle for the oral delivery of insulin. Nanomedicine UK 7 (2012), 1311–1337.
47. [47] Yun, Y., Cho, Y.W., Park, K., Nanoparticles for oral delivery: targeted nanoparticles with peptidic ligands for oral protein delivery. Adv. Drug Deliv. Rev. 65 (2013), 822–832.
48. [48] Sonaje, K., Lin, Y.H., Juang, J.H., Wey, S.P., Chen, C.T., Sung, H.W., In vivo evaluation of safety and efficacy of self-assembled nanoparticles for oral insulin delivery. Biomaterials 30 (2009), 2329–2339.
49. [49] Sonaje, K., Chen, Y.J., Chen, H.L., Wey, S.P., Juang, J.H., Nguyen, H.N., Hsu, C.W., Lin, K.J., Sung, H.W., Enteric-coated capsules filled with freeze-dried chitosan/poly(gamma-glutamic acid) nanoparticles for oral insulin delivery. Biomaterials 31 (2010), 3384–3394.
50. [50] Woitiski, C.B., Neufeld, R.J., Veiga, F., Carvalho, R.A., Figueiredo, I.V., Pharmacological effect of orally delivered insulin facilitated by multilayered stable nanoparticles. Eur. J. Pharm. Sci. 41 (2010), 556–563.
51. [51] Nguyen, H.N., Wey, S.P., Juang, J.H., Sonaje, K., Ho, Y.C., Chuang, E.Y., Hsu, C.W., Yen, T.C., Lin, K.J., Sung, H.W., The glucose-lowering potential of exendin-4 orally delivered via a pH-sensitive nanoparticle vehicle and effects on subsequent insulin secretion in vivo. Biomaterials 32 (2011), 2673–2682.
52. [52] Lalatsa, A., Lee, V., Malkinson, J.P., Zloh, M., Schatzlein, A.G., Uchegbu, I.F., A prodrug nanoparticle approach for the oral delivery of a hydrophilic peptide, leucine(5)-enkephalin, to the brain. Mol. Pharm. 9 (2012), 1665–1680.
53. [53] Sonaje, K., Lin, K.J., Wey, S.P., Lin, C.K., Yeh, T.H., Nguyen, H.N., Hsu, C.W., Yen, T.C., Juang, J.H., Sung, H.W., Biodistribution, pharmacodynamics and pharmacokinetics of insulin analogues in a rat model: oral delivery using pH-responsive nanoparticles vs. subcutaneous injection. Biomaterials 31 (2010), 6849–6858.
54. [54] Su, F.Y., Lin, K.J., Sonaje, K., Wey, S.P., Yen, T.C., Ho, Y.C., Panda, N., Chuang, E.Y., Maiti, B., Sung, H.W., Protease inhibition and absorption enhancement by functional nanoparticles for effective oral insulin delivery. Biomaterials 33 (2012), 2801–2811.
55. [55] Chuang, E.Y., Lin, K.J., Su, F.Y., Chen, H.L., Maiti, B., Ho, Y.C., Yen, T.C., Panda, N., Sung, H.W., Calcium depletion-mediated protease inhibition and apical–junctional-complex disassembly via an EGTA-conjugated carrier for oral insulin delivery. J. Control. Release 169 (2013), 296–305.
56. [56] Li, X.Y., Guo, S.Y., Zhu, C.L., Zhu, Q.L., Gan, Y., Rantanen, J., Rahbek, U.L., Hovgaard, L., Yang, M.S., Intestinal mucosa permeability following oral insulin delivery using core shell corona nanolipoparticles. Biomaterials 34 (2013), 9678–9687.
57. [57] Cui, F., Shi, K., Zhang, L., Tao, A., Kawashima, Y., Biodegradable nanoparticles loaded with insulin-phospholipid complex for oral delivery: preparation, in vitro characterization and in vivo evaluation. J. Control. Release 114 (2006), 242–250.
58. [58] Cui, F.D., Tao, A.J., Cun, D.M., Zhang, L.Q., Shi, K., Preparation of insulin loaded PLGA-Hp55 nanoparticles for oral delivery. J. Pharm. Sci. 96 (2007), 421–427.
59. [59] Sharma, G., van der Walle, C.F., Ravi Kumar, M.N., Antacid co-encapsulated polyester nanoparticles for peroral delivery of insulin: development, pharmacokinetics, biodistribution and pharmacodynamics. Int. J. Pharm. 440 (2013), 99–110.
60. [60] Wu, Z.M., Zhou, L., Guo, X.D., Jiang, W., Ling, L., Qian, Y., Luo, K.Q., Zhang, L.J., HP55-coated capsule containing PLGA/RS nanoparticles for oral delivery of insulin. Int. J. Pharm. 425 (2012), 1–8.
61. [61] Wang, K., Qi, J., Weng, T., Tian, Z., Lu, Y., Hu, K., Yin, Z., Wu, W., Enhancement of oral bioavailability of cyclosporine a: comparison of various nanoscale drug-delivery systems. Int. J. Nanomedicine 9 (2014), 4991–4999.
62. [62] Onoue, S., Suzuki, H., Kojo, Y., Matsunaga, S., Sato, H., Mizumoto, T., Yuminoki, K., Hashimoto, N., Yamada, S., Self-micellizing solid dispersion of cyclosporine A with improved dissolution and oral bioavailability. Eur. J. Pharm. Sci. 62 (2014), 16–22.
63. [63] Lai, J., Lu, Y., Yin, Z., Hu, F., Wu, W., Pharmacokinetics and enhanced oral bioavailability in beagle dogs of cyclosporine A encapsulated in glyceryl monooleate/poloxamer 407 cubic nanoparticles. Int. J. Nanomedicine 5 (2010), 13–23.
64. [64] Qu, W., Li, Y., Hovgaard, L., Li, S., Dai, W., Wang, J., Zhang, X., Zhang, Q., A silica-based pH-sensitive nanomatrix system improves the oral absorption and efficacy of incretin hormone glucagon-like peptide-1. Int. J. Nanomedicine 7 (2012), 4983–4994.
65. [65] Dai, W.B., Guo, Y.L., Zhang, H., Wang, X.Q., Zhang, Q., Sylysia 350/Eudragit S100 solid nanomatrix as a promising system for oral delivery of cyclosporine A. Int. J. Pharm. 478 (2015), 718–725.
66. [66] Zhang, Z.H., Zhang, Y.L., Zhou, J.P., Lv, H.X., Solid lipid nanoparticles modified with stearic acid-octaarginine for oral administration of insulin. Int. J. Nanomedicine 7 (2012), 3333–3339.
67. [67] Rao, S.V., Yajurvedi, K., Shao, J., Self-nanoemulsifying drug delivery system (SNEDDS) for oral delivery of protein drugs: III. In vivo oral absorption study. Int. J. Pharm. 362 (2008), 16–19.
68. [68] Hintzen, F., Perera, G., Hauptstein, S., Muller, C., Laffleur, F., Bernkop-Schnurch, A., In vivo evaluation of an oral self-microemulsifying drug delivery system (SMEDDS) for leuprorelin. Int. J. Pharm. 472 (2014), 20–26.
69. [69] Agrawal, A.K., Harde, H., Thanki, K., Jain, S., Improved stability and antidiabetic potential of insulin containing folic acid functionalized polymer stabilized multilayered liposomes following oral administration. Biomacromolecules 15 (2014), 350–360.
70. [70] Chen, D., Xia, D., Li, X., Zhu, Q., Yu, H., Zhu, C., Gan, Y., Comparative study of Pluronic((R)) F127-modified liposomes and chitosan-modified liposomes for mucus penetration and oral absorption of cyclosporine A in rats. Int. J. Pharm. 449 (2013), 1–9.
71. [71] Fu, C., Liu, T., Li, L., Liu, H., Chen, D., Tang, F., The absorption, distribution, excretion and toxicity of mesoporous silica nanoparticles in mice following different exposure routes. Biomaterials 34 (2013), 2565–2575.
72. [72] Andreani, T., de Souza, A.L., Kiill, C.P., Lorenzon, E.N., Fangueiro, J.F., Calpena, A.C., Chaud, M.V., Garcia, M.L., Gremiao, M.P., Silva, A.M., Souto, E.B., Preparation and characterization of PEG-coated silica nanoparticles for oral insulin delivery. Int. J. Pharm. 473 (2014), 627–635.
73. [73] Mahkam, M., Hosseinzadeh, F., Galehassadi, M., Preparation of ionic liquid functionalized silica nanoparticles for oral drug delivery. J. Biomater. Nanobiotechnol. 3 (2012), 391–395.
74. 2-HP55 (insulin-loaded silica coating HP55) for oral delivery of insulin. Int. J. Pharm. 454 (2013), 278–284.
75. [75] Bhumkar, D.R., Joshi, H.M., Sastry, M., Pokharkar, V.B., Chitosan reduced gold nanoparticles as novel carriers for transmucosal delivery of insulin. Pharm. Res. Dordr. 24 (2007), 1415–1426.
76. [76] Guo, J.F., Rahme, K., Fitzgerald, K.A., Holmes, J.D., O'Driscoll, C.M., Biomimetic gold nanocomplexes for gene knockdown: will gold deliver dividends for small interfering RNA nanomedicines?. Nano Res. 8 (2015), 3111–3140.
77. [77] Trevaskis, N.L., Kaminskas, L.M., Porter, C.J., From sewer to saviour — targeting the lymphatic system to promote drug exposure and activity. Nat. Rev. Drug Discov. 14 (2015), 781–803.
78. [78] O'Driscoll, C.M., Anatomy and Physiology of the Lymphatics. Charman, W.N., Stella, V.J., (eds.) Lymphatic Transport of Drugs, 1992, Taylor and Francis Group, 1–35.
79. [79] Griffin, B.T., O'Driscoll, C.M., Opportunities and challenges for oral delivery of hydrophobic versus hydrophilic peptide and protein-like drugs using lipid-based technologies. Ther. Deliv. 2 (2011), 1633–1653.
80. [80] Shete, H.K., Selkar, N., Vanage, G.R., Patravale, V.B., Tamoxifen nanostructured lipid carriers: enhanced in vivo antitumor efficacy with reduced adverse drug effects. Int. J. Pharm. 468 (2014), 1–14.
81. [81] Estella-Hermoso de Mendoza, A., Campanero, M.A., Lana, H., Villa-Pulgarin, J.A., de la Iglesia-Vicente, J., Mollinedo, F., Blanco-Prieto, M.J., Complete inhibition of extranodal dissemination of lymphoma by edelfosine-loaded lipid nanoparticles. Nanomedicine (London) 7 (2012), 679–690.
82. [82] Attili-Qadri, S., Karra, N., Nemirovski, A., Schwob, O., Talmon, Y., Nassar, T., Benita, S., Oral delivery system prolongs blood circulation of docetaxel nanocapsules via lymphatic absorption. Proc. Natl. Acad. Sci. U. S. A. 110 (2013), 17498–17503.
83. [83] Chuang, E.Y., Nguyen, G.T., Su, F.Y., Lin, K.J., Chen, C.T., Mi, F.L., Yen, T.C., Juang, J.H., Sung, H.W., Combination therapy via oral co-administration of insulin- and exendin-4-loaded nanoparticles to treat type 2 diabetic rats undergoing OGTT. Biomaterials 34 (2013), 7994–8001.
84. [84] Su, F.Y., Chuang, E.Y., Lin, P.Y., Chou, Y.C., Chen, C.T., Mi, F.L., Wey, S.P., Yen, T.C., Lin, K.J., Sung, H.W., Treatment of chemotherapy-induced neutropenia in a rat model by using multiple daily doses of oral administration of G-CSF-containing nanoparticles. Biomaterials 35 (2014), 3641–3649.
85. [85] Semete, B., Booysen, L., Kalombo, L., Ramalapa, B., Hayeshi, R., Swai, H.S., Effects of protein binding on the biodistribution of PEGylated PLGA nanoparticles post oral administration. Int. J. Pharm. 424 (2012), 115–120.
86. [86] Zhang, X., Sun, M., Zheng, A., Cao, D., Bi, Y., Sun, J., Preparation and characterization of insulin-loaded bioadhesive PLGA nanoparticles for oral administration. Eur. J. Pharm. Sci. 45 (2012), 632–638.
87. [87] Alves, A.C., Gontijo, C.M., Oliveira, M.C., Diniz, S.O.F., Oliveira, F.M., Cardoso, V.N., Ramaldes, G.A., Biodistribution of free 99mTc-ovalbumin and 99MTc-ovalbumin encapsulated in liposomes. Braz. Arch. Biol. Technol. 48 (2005), 235–241.
88. [88] Bimbo, L.M., Sarparanta, M., Santos, H.A., Airaksinen, A.J., Makila, E., Laaksonen, T., Peltonen, L., Lehto, V.P., Hirvonen, J., Salonen, J., Biocompatibility of thermally hydrocarbonized porous silicon nanoparticles and their biodistribution in rats. ACS Nano 4 (2010), 3023–3032.
89. [89] Yang, L., Lee, Y.C., Il Kim, M., Park, H.G., Huh, Y.S., Shao, Y.T., Han, H.K., Biodistribution and clearance of aminoclay nanoparticles: implication for in vivo applicability as a tailor-made drug delivery carrier. J. Mater. Chem. B 2 (2014), 7567–7574.
90. [90] Falzarano, M.S., Passarelli, C., Bassi, E., Fabris, M., Perrone, D., Sabatelli, P., Maraldi, N.M., Dona, S., Selvatici, R., Bonaldo, P., Sparnacci, K., Laus, M., Braghetta, P., Rimessi, P., Ferlini, A., Biodistribution and molecular studies on orally administered nanoparticle–AON complexes encapsulated with alginate aiming at inducing dystrophin rescue in mdx mice. Biomed. Res. Int., 2013.
91. [91] Liu, Y., Kong, M., Feng, C., Yang, K.K., Li, Y., Su, J., Cheng, X.J., Park, H.J., Chen, X.G., Biocompatibility, cellular uptake and biodistribution of the polymeric amphiphilic nanoparticles as oral drug carriers. Colloids Surf. B 103 (2013), 345–353.
92. [92] Areses, P., Agueros, M.T., Quincoces, G., Collantes, M., Richter, J.A., Lopez-Sanchez, L.M., Sanchez-Martinez, M., Irache, J.M., Penuelas, I., Molecular imaging techniques to study the biodistribution of orally administered Tc-99m-labelled naive and ligand-tagged nanoparticles. Mol. Imaging Biol. 13 (2011), 1215–1223.
93. [93] Wilson, D.S., Dalmasso, G., Wang, L.X., Sitaraman, S.V., Merlin, D., Murthy, N., Orally delivered thioketal nanoparticles loaded with TNF-alpha-siRNA target inflammation and inhibit gene expression in the intestines. Nat. Mater. 9 (2010), 923–928.
94. [94] Makhlof, A., Werle, M., Tozuka, Y., Takeuchi, H., A mucoadhesive nanoparticulate system for the simultaneous delivery of macromolecules and permeation enhancers to the intestinal mucosa. J. Control. Release 149 (2011), 81–88.
95. [95] Tobio, M., Sanchez, A., Vila, A., Soriano, I., Evora, C., Vila-Jato, J.L., Alonso, M.J., The role of PEG on the stability in digestive fluids and in vivo fate of PEG–PLA nanoparticles following oral administration. Colloids Surf. B 18 (2000), 315–323.
96. [96] Reineke, J.J., Cho, D.Y., Dingle, Y.T., Morello, A.P., Jacob, J., Thanos, C.G., Mathiowitz, E., Unique insights into the intestinal absorption, transit, and subsequent biodistribution of polymer-derived microspheres. Proc. Natl. Acad. Sci. U. S. A. 110 (2013), 13803–13808.
97. [97] Bakhru, S.H., Furtado, S., Morello, A.P., Mathiowitz, E., Oral delivery of proteins by biodegradable nanoparticles. Adv. Drug Deliv. Rev. 65 (2013), 811–821.
98. [98] Thygesen, P., Macheras, P., Van Peer, A., Physiologically-based PK/PD modelling of therapeutic macromolecules. Pharm. Res. 26 (2009), 2543–2550.
99. [99] Rostami-Hodjegan, A., Physiologically based pharmacokinetics joined with in vitro-in vivo extrapolation of ADME: a marriage under the arch of systems pharmacology. Clin. Pharmacol. Ther. 92 (2012), 50–61.
100. [100] Khalil, F., Laer, S., Physiologically based pharmacokinetic modeling: methodology, applications, and limitations with a focus on its role in pediatric drug development. J. Biomed. Biotechnol., 2011.
101. [101] Moss, D.M., Siccardi, M., Optimizing nanomedicine pharmacokinetics using physiologically based pharmacokinetics modelling. Brit. J. Pharmacol. 171 (2014), 3963–3979.
102. [102] Diao, L., Meibohm, B., Tools for predicting the PK/PD of therapeutic proteins. Expert Opin. Drug Metab. Toxicol. 11 (2015), 1115–1125.
103. [103] Offman, E., Edginton, A.N., A PBPK workflow for first-in-human dose selection of a subcutaneously administered pegylated peptide. J. Pharmacokinet. Pharmacodyn. 42 (2015), 135–150.
104. [104] Li, M., Al-Jamal, K.T., Kostarelos, K., Reineke, J., Physiologically based pharmacokinetic modeling of nanoparticles. ACS Nano 4 (2010), 6303–6317.
105. [105] Khalil, F., Laer, S., Physiologically based pharmacokinetic models in the prediction of oral drug exposure over the entire pediatric age range-sotalol as a model drug. AAPS J. 16 (2014), 226–239.
106. [106] Kostewicz, E.S., Aarons, L., Bergstrand, M., Bolger, M.B., Galetin, A., Hatley, O., Jamei, M., Lloyd, R., Pepin, X., Rostami-Hodjegan, A., Sjogren, E., Tannergren, C., Turner, D.B., Wagner, C., Weitschies, W., Dressman, J., PBPK models for the prediction of in vivo performance of oral dosage forms. Eur. J. Pharm. Sci. 57 (2014), 300–321.
107. [107] Jones, H., Rowland-Yeo, K., Basic concepts in physiologically based pharmacokinetic modeling in drug discovery and development. CPT Pharmacometrics Syst Pharmacol., 2, 2013, e63.
108. [108] Li, D., Emond, C., Johanson, G., Jolliet, O., Using a PBPK model to study the influence of different characteristics of nanoparticles on their biodistribution. J. Phys. Conf. Ser., 429, 2013.
109. [109] Crommelin, D.J., Florence, A.T., Towards more effective advanced drug delivery systems. Int. J. Pharm. 454 (2013), 496–511.
110. [110] Araujo, F., Shrestha, N., Granja, P.L., Hirvonen, J., Santos, H.A., Sarmento, B., Safety and toxicity concerns of orally delivered nanoparticles as drug carriers. Expert Opin. Drug Metab. Toxicol. 11 (2015), 381–393.
111. [111] Eichler, H.G., Baird, L.G., Barker, R., Bloechl-Daum, B., Borlum-Kristensen, F., Brown, J., Chua, R., Del Signore, S., Dugan, U., Ferguson, J., Garner, S., Goettsch, W., Haigh, J., Honig, P., Hoos, A., Huckle, P., Kondo, T., Le Cam, Y., Leufkens, H., Lim, R., Longson, C., Lumpkin, M., Maraganore, J., O'Rourke, B., Oye, K., Pezalla, E., Pignatti, F., Raine, J., Rasi, G., Salmonson, T., Samaha, D., Schneeweiss, S., Siviero, P.D., Skinner, M., Teagarden, J.R., Tominaga, T., Trusheim, M.R., Tunis, S., Unger, T.F., Vamvakas, S., Hirsch, G., From adaptive licensing to adaptive pathways: delivering a flexible life-span approach to bring new drugs to patients. Clin. Pharmacol. Ther. 97 (2015), 234–246.
112. [112] Ehmann, F., Sakai-Kato, K., Duncan, R., de la Ossa, D. Hernan Perez, Pita, R., Vidal, J.M., Kohli, A., Tothfalusi, L., Sanh, A., Tinton, S., Robert, J.L., Lima, B. Silva, Amati, M.P., Next-generation nanomedicines and nanosimilars: EU regulators’ initiatives relating to the development and evaluation of nanomedicines. Nanomedicine (London) 8 (2013), 849–856.